ERIN O'NEAL: Open Payments
NPI 1326594482 · HATTIESBURG, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,110 in 67 payments from 14 companies in 2025. Trend: 2023 $175 · 2024 $119 · 2025 $1,110
Food & beverage: $1,110
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $366 |
| Novo Nordisk Inc | 11 | $141 |
| Lilly USA, LLC | 8 | $132 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $77 |
| PFIZER INC. | 3 | $77 |
| Tris Pharma Inc | 3 | $61 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $56 |
| Amgen Inc. | 3 | $45 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $35 |
| Novartis Pharmaceuticals Corporation | 1 | $34 |
Products named: QULIPTA, MOUNJARO, VRAYLAR, UBRELVY, XIFAXAN, PREVNAR 20, Dyanavel XR, JARDIANCE.
Industry payments across MS — which companies pay providers there.
